Clinuvel Pharmaceuticals Ltd (CUV) - Total Liabilities
Based on the latest financial reports, Clinuvel Pharmaceuticals Ltd (CUV) has total liabilities worth AU$20.68 Million AUD (≈ $14.63 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CUV strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Clinuvel Pharmaceuticals Ltd - Total Liabilities Trend (2000–2025)
This chart illustrates how Clinuvel Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Clinuvel Pharmaceuticals Ltd balance sheet assets.
Clinuvel Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Clinuvel Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Western Financial Inc
NASDAQ:MYFW
|
USA | $2.96 Billion |
|
PRUKSA HOLDING
BK:PSH-R
|
Thailand | ฿24.59 Billion |
|
ALPHA
KLSE:0303
|
Malaysia | RM58.34 Million |
|
Tianjin Hi-Tech Development Co Ltd
SHG:600082
|
China | CN¥844.47 Million |
|
Gannett Co Inc
NYSE:GCI
|
USA | $1.68 Billion |
|
Forafric Global PLC Ordinary Shares
NASDAQ:AFRI
|
USA | $240.28 Million |
|
Shanghai Huaming Intelligent Terminal Equipment Co Ltd
SHE:300462
|
China | CN¥420.31 Million |
|
Bohai Water Industry Co Ltd
SHE:000605
|
China | CN¥5.21 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Clinuvel Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CUV equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clinuvel Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clinuvel Pharmaceuticals Ltd (2000–2025)
The table below shows the annual total liabilities of Clinuvel Pharmaceuticals Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$30.94 Million ≈ $21.89 Million |
+10.06% |
| 2024-06-30 | AU$28.11 Million ≈ $19.89 Million |
-5.96% |
| 2023-06-30 | AU$29.89 Million ≈ $21.15 Million |
+55.25% |
| 2022-06-30 | AU$19.25 Million ≈ $13.62 Million |
+95.88% |
| 2021-06-30 | AU$9.83 Million ≈ $6.96 Million |
+3.75% |
| 2020-06-30 | AU$9.48 Million ≈ $6.70 Million |
+83.43% |
| 2019-06-30 | AU$5.17 Million ≈ $3.65 Million |
+48.07% |
| 2018-06-30 | AU$3.49 Million ≈ $2.47 Million |
+10.30% |
| 2017-06-30 | AU$3.16 Million ≈ $2.24 Million |
+37.30% |
| 2016-06-30 | AU$2.30 Million ≈ $1.63 Million |
-5.53% |
| 2015-06-30 | AU$2.44 Million ≈ $1.73 Million |
+41.30% |
| 2014-06-30 | AU$1.73 Million ≈ $1.22 Million |
-12.64% |
| 2013-06-30 | AU$1.98 Million ≈ $1.40 Million |
-16.22% |
| 2012-06-30 | AU$2.36 Million ≈ $1.67 Million |
-37.24% |
| 2011-06-30 | AU$3.76 Million ≈ $2.66 Million |
+21.97% |
| 2010-06-30 | AU$3.08 Million ≈ $2.18 Million |
-32.48% |
| 2009-06-30 | AU$4.56 Million ≈ $3.23 Million |
+44.56% |
| 2008-06-30 | AU$3.16 Million ≈ $2.23 Million |
+29.73% |
| 2007-06-30 | AU$2.43 Million ≈ $1.72 Million |
-21.06% |
| 2006-06-30 | AU$3.08 Million ≈ $2.18 Million |
+18.48% |
| 2005-06-30 | AU$2.60 Million ≈ $1.84 Million |
+86.82% |
| 2004-06-30 | AU$1.39 Million ≈ $985.24K |
+160.05% |
| 2003-06-30 | AU$535.45K ≈ $378.87K |
+153.98% |
| 2002-06-30 | AU$210.83K ≈ $149.17K |
-33.76% |
| 2001-06-30 | AU$318.26K ≈ $225.19K |
+157.62% |
| 2000-06-30 | AU$123.54K ≈ $87.41K |
-- |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more